Literature DB >> 16981667

Long-term results of the MRC AML10 trial.

Alan K Burnett1, Keith Wheatley, Anthony H Goldstone, Richard Stevens, Ian Hann, Robert K Hills.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16981667

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  6 in total

1.  Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.

Authors:  Zhichao Li; Yinmei Liu; Qing Wang; Linjun Chen; Liyuan Ma; Siguo Hao
Journal:  Acta Haematol       Date:  2019-02-26       Impact factor: 2.195

2.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Authors:  J Schetelig; M Schaich; K Schäfer-Eckart; M Hänel; W E Aulitzky; H Einsele; N Schmitz; W Rösler; M Stelljes; C D Baldus; A D Ho; A Neubauer; H Serve; J Mayer; W E Berdel; B Mohr; U Oelschlägel; S Parmentier; C Röllig; M Kramer; U Platzbecker; T Illmer; C Thiede; M Bornhäuser; G Ehninger
Journal:  Leukemia       Date:  2014-12-01       Impact factor: 11.528

3.  Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Authors:  J J Cornelissen; J Versluis; J R Passweg; W L J van Putten; M G Manz; J Maertens; H B Beverloo; P J M Valk; M van Marwijk Kooy; P W Wijermans; M R Schaafsma; B J Biemond; M-C Vekemans; D A Breems; L F Verdonck; M F Fey; M Jongen-Lavrencic; J J W M Janssen; G Huls; J Kuball; T Pabst; C Graux; H C Schouten; A Gratwohl; E Vellenga; G Ossenkoppele; B Löwenberg
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

Review 4.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Authors:  John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

5.  Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.

Authors:  Dandan Li; Li Wang; Honghu Zhu; Liping Dou; Daihong Liu; Lin Fu; Cong Ma; Xuebin Ma; Yushi Yao; Lei Zhou; Qian Wang; Lijun Wang; Yu Zhao; Yu Jing; Lili Wang; Yonghui Li; Li Yu
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

6.  Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

Authors:  Juan Montoro; Izaskun Ceberio; Patrick Hilden; Molly A Maloy; Juliet Barker; Hugo Castro-Malaspina; Parastoo Dahi; Guenther Koehne; Miguel-Angel Perales; Doris Ponce; Craig Sauter; Brian Shaffer; Roni Tamari; James W Young; Sergio A Giralt; Richard J O'Reilly; Ann A Jakubowski; Esperanza B Papadopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-13       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.